Investorideas podcasts on iTunes, Google Play Music and potcasts - cannabis news and stocks to watch plus insight from thought leaders and experts crypto corner    Play by Play – the latest sports headlines and sports stock news    420 Cannabis Investor Ideas Call us 800 665 0411


Join our smart investors - Get the best stock directories in  blockchain, cannabis, crypto, AI, IoT, cleantech. Daily podcasts in cannabis and crpto. Just $99  a year

Republican Senate Candidate Dom Gentile Announces Support for #MedicalCannabis Legislation


BIRMINGHAM, Ala. - May 31, 2017 ( Newswire) Alabama candidate for U.S. Senate, Dom Gentile, today announced his support for medical cannabis, and is adding this issue to his campaign platform at

"I have recently met with dozens of people who are stricken with medical conditions such as epilepsy, seizures, severe autism, Alzheimer's and MS. Many of them have symptoms that can be relieved by cannabis that is specifically formulated for medical use. As I listened to the passionate pleas of these patients and their families, and understood how this can help them, I became a believer that something needed to be done at the federal level," said Gentile. "Medical cannabis is listed as a Schedule 1 controlled substance under the Controlled Substances Act of 1970. It is in the same class as heroin and LSD, and that is absurd. I am calling for the FDA and the DEA to immediately re-classify cannabis for medical use and allow the states to decide how to dispense the drug."

"We just need to apply some common sense here and let families have access to the drugs they need to get relief," added Gentile. "Medical cannabis helps a number of chronic conditions and illnesses – from autistic children to adults fighting cancer, we just need to do the right thing and allow access to a drug that can provide relief."

Gentile also says, "My stance on medical cannabis in no way whatsoever an endorsement for the legalization of the recreational use of marijuana. I am strictly opposed to this."

Gentile adds, "In this case, it is clear that the enormously powerful pharmaceutical lobby has no interest in supporting a product that cannot be patented like opioid drugs, because that will cost them a lot of money. This is just another reason why the people of this country need to throw out the old style politicians who take money from special interests and support candidates who have never, and will never, accept money from PACs and special interests. We need to focus on the people."

About Dom Gentile

Gentile's campaign story, travel schedule and conversations with constituents will be documented on his website and social media. You can follow his journey to victory on Facebook, Instagram and Twitter @DomForSenate.

Media interested in interviews can contact Helen Todd at 205.907.3374 or email:

Paid for by Gentile for Alabama.


Gentile for Senate
Helen Todd, APR, 205-907-3374

Marijuana / Hemp Stocks

Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory

Join our Group on Linkedin - Marijuana / Hemp Stocks - News and Trends in Green Investing

Global Cannabis Investing - features Investor Ideas Cannabis news

Get News Alerts on Marijuana Stocks

Watch the 420 Cannabis Investor video

More Info: Newswire

This news is published on the Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: Learn more about publishing your news release on the newswire

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: Global investors must adhere to regulations of each country.

Please read privacy policy: